



Date: 22/10/2024

To,
The Deputy Manager,
The Department of Corporate Services,
National Stock Exchange Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra(E), Mumbai-400051

REF: SCRIP CODE: CROWN ISIN: INE491V01019

Sub: Submission of Newspaper Copies of publication of Unaudited Financial Results of the Company for quarter and half year ended on September 30, 2024.

Dear Sir/ Madam,

In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has published an Extract of Statement of Unaudited Standalone Financial Results of the Company for the quarter and half year ended on September 30, 2024, which have been considered, approved and taken on record by the Board of Directors, at their meeting held on Monday, October 21, 2024.

The said financial results have been published in "Business Standard" (English Newspaper) edition dated 22/10/2024 & in "Mumbai Lakshwadeep" (Marathi newspaper) edition dated 22/10/2024

Further, in pursuance of Regulation 30 read with Part A of Schedule III enclosed herewith please find below the copy of Newspaper articles as published in above mentioned newspapers.

Kindly take the same on your record and oblige.

Thanking You,

Yours faithfully,

Yours Faithfully,
For, CROWN LIFTERS LIMITED

KARIM K JARIA
CHAIRMAN & MANAGING DIRECTOR
DIN:00200320

CROWN LIFTERS LIMITED
104, Raheja Plaza, Shah Industrial Estate, Veera Desai Road, Andheri(W), Mumbai -400053, India.
Tel: +912240062829 | Email: cs@crownlifters.com | www.crownlifters.com
CIN:L74210MH2002PLC138439



NOTICE CUM ADDENDA

DSP ASSET MANAGERS

DSP Equity & Bond Fund
(An open ended hybrid scheme investing predominantly in equity and equity related instruments)

This product is suitable for investors who are seeking:
• Capital growth and income over a long-term investment horizon
• Investment primarily in equity/equity-related securities, with balance exposure in money market and debt securities

*Investors should consult their financial advisers if in doubt about whether the Scheme is suitable for them.



(For latest Riskometers, investors may refer on the website of the Fund viz: www.dspim.com)

Unit holders are requested to update their PAN, KYC, email address, mobile number, nominee details with AMC and are also advised to link their PAN with Aadhar Number. Further, Unit holders can view the Investor Charter available on website of the Fund as well as check for any unclaimed redemptions or Income Distribution cum Capital Withdrawal (IDCW) payments.

Place: Mumbai
Date: October 22, 2024

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

CROWN LIFTERS LIMITED
CIN: L74210MH2002PLC138439
Registered Office: 104, Rahejs Plaza Premises Co-Op Soc. Ltd., Shah Industrial Estate, Veera Dasai Rd, Andheri (W) Mumbai - 400053.
Tel No: +91 +91 22 4006 2829; E-mail: cs.cli@crownlifters.com; Website: www.crownlifters.com

Statement of Financial Results for the Quarter Ended on September 30th, 2024 (Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended		Six Months Ended		Year Ended
		30-09-2024 (Un-Audited)	30-06-2024 (Un-Audited)	30-09-2023 (Un-Audited)	30-09-2024 (Un-Audited)	31-03-2024 (Audited)
1	Total Income from Operations (Net)	798.51	793.30	539.92	1591.81	1063.06
2	Net Profit / (Loss) for the period (before tax & Exceptional Items)	284.76	233.90	105.15	518.66	222.25
3	Net Profit / (Loss) for the period before Tax (after Exceptional Items)	285.21	1461.94	105.15	1747.15	222.25
4	Net Profit / (Loss) for the period after Tax (after Exceptional Items)	212.80	1095.66	105.15	1308.46	222.25
5	Total Comprehensive Income (Comprising Profit / (Loss) after Tax and Other Comprehensive Income after Tax)	212.80	1095.66	105.15	1308.46	222.25
6	Equity Share Capital	1122.33	1122.33	1041.00	1122.33	1041.00
7	Reserves excluding Revaluation Reserve as at Balance Sheet date	3793.42	3580.62	1294.30	3793.42	1294.30
8	Earnings Per Share (of Rs. 10 each, in Rs.)					
8	Basic	1.90	9.76	1.01	11.66	2.13
8	Diluted	1.90	9.76	1.01	11.66	2.13

NOTES:
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The full format of the financial result is available on the Stock Exchange websites: www.nseindia.com & company's website: www.crownlifters.com.

On behalf of the Board of Directors
CROWN LIFTERS LIMITED
507,
Mr. Nizar Nooruddin Rajwani - Director & Chief Financial Officer
DIN: 03312143

Place : Mumbai
Date : 21.10.2024

MAHINDRA MANULIFE INVESTMENT MANAGEMENT PRIVATE LIMITED
Corporate Identity Number: U65900MH2013PTC244758
Registered Office: 'A' Wing, 4th Floor, Mahindra Towers, Dr. G.M. Bhosale Marg, RK. Karve Chowk, Worli, Mumbai 400 018
Corporate Office: Unit No. 204, 2nd Floor, Amiti Building, Praram Agastya Corporate Park, LBS Road, Kamasa Junction, Kurla (West), Mumbai - 400 070
Tel: 1800-4196244; website: www.mahindramanulife.com; email: mf.invest@mahindramanulife.com

NOTICE NO. 32/2024

Notice is hereby given to the investor(s)/unit holder(s) of the scheme(s) of Mahindra Manulife Mutual Fund ("the Fund") that in accordance with Regulation 59 of SEBI (Mutual Funds) Regulations, 1996 read with Clause 5.3 of SEBI Master Circular No. SEBI/HQ/IMD/IMD-PoD-1/PCIR/2024/90 dated June 27, 2024, the unaudited half yearly financial results of all the scheme(s) of Mahindra Manulife Mutual Fund ("the Fund") for the period ended September 30, 2024, is hosted on the Fund's website www.mahindramanulife.com in a user - friendly and downloadable format.

Investor(s)/unit holder(s) are requested to take a note of the same.

For Mahindra Manulife Investment Management Private Limited
Place: Mumbai
Date: October 21, 2024
Authorised Signatory

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

50 years of opinion that shapes opinions.



50 Years of Insight

MPL Mukka Proteins Limited
MUKKA PROTEINS LIMITED
Regd. Office: Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Atlayara, Dakshina Kannada, Mangaluru - 575001, Karnataka.
Tel: +918244252889; Email: investors@mukkaproteins.com
Website: www.mukkaproteins.com CIN: L05004KA2010PLC055771

INFORMATION REGARDING THE EXTRA-ORDINARY GENERAL MEETING TO BE HELD THROUGH VIDEO CONFERENCING/OTHER AUDIO-VISUAL MEANS

Members may please note that the Extra-Ordinary General Meeting ("EGM") of Mukka Proteins Limited ("the Company") will be held on Saturday, 16th day of November 2024 at 03:00 PM (IST), through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") in compliance with the applicable provisions of the Companies Act, 2013 read with rules framed thereunder and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with the General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 02/2021 dated January 13, 2021, General Circular No. 19/2021 dated December 08, 2021 and General Circular No. 21/2021 dated December 14, 2021 and General Circular No. 2/2022 dated May 05, 2022 and General Circular No. 10/2022 dated December 28, 2022 and General Circular No. 09/2023 dated September 25, 2023 and General Circular No. 09/2024 dated September 19, 2024 issued by the Ministry of Corporate Affairs ("MCA") and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/ CIR/2023/167 dated October 7, 2023 and Circular No. SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CI/2024/133 dated October 3, 2024 issued by Securities and Exchange Board of India ("SEBI") (hereinafter collectively referred to as "Circulars"). The deemed venue for the EGM shall be the Registered Office of the Company. As the EGM is being convened through VC/OAVM, physical presence of the Members at the venue is not required.

In compliance with the above referred Circulars, the Notice of the EGM will be sent, in due course, only by e-mail to those Members, whose e-mail address is registered with their Depository Participants ("DP"). Members may take note that the aforesaid documents will also be available on the Company's website at www.mukkaproteins.com, website of BSE Limited at www.bseindia.com and website of National Stock Exchange of India Limited at www.nseindia.com.

Manner of casting votes and attending EGM:
Remote e-voting (prior to EGM) and e-voting (during the EGM) facility will be provided to all Members to cast their votes on all the resolutions set out in Notice of the EGM. Detailed instructions for remote e-voting and e-voting during the EGM will be provided in Notice of the EGM.

Members can join and participate in the EGM through VC/OAVM facility only. Members participating through VC/OAVM facility shall be counted for the purpose of reckoning quorum under Section 103 of the Act. Detailed instructions for joining the EGM through VC/OAVM will be provided in the Notice of the EGM.

Manner of registering/updating e-mail address and other details:
Members holding shares in Demat form are advised to register/update the particulars of their e-mail address, bank account, change of postal address and mobile number etc. to their respective DPs. The e-mail address registered with the DPs will be used for sending all the communications.

The above information is being issued for the information and benefit of all the Members of the Company.

For and on behalf of the Board of Directors
Mukka Proteins Limited
Sd/-
Kalandan Mohammed Haris
Managing Director & CEO

Place : Mangaluru
Date : 21-10-2024

SOLARA ACTIVE PHARMA SCIENCES LIMITED
CIN: L24230MH2017PLC291638
Regd. Office: No. 201 Devarajasa, Sector 17, Vashi, Navi Mumbai 400 703.
Address: 2nd Floor, Admin Block 27, Vandaloor kelambakkam Road, Keelakottaiyur Village, Chennai 600 127.

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024 (Rs. in Crores except per share data)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous Financial Year ended
		30.09.2024 UNAUDITED	30.06.2024 UNAUDITED	30.09.2023 UNAUDITED	30.09.2024 UNAUDITED	30.09.2023 UNAUDITED	31.03.2024 AUDITED
Continuing operations:							
1	Total income from operations	346.95	363.49	425.24	710.44	777.55	1268.22
2	Net Profit for the period before tax (before exceptional items)	8.01	(13.46)	(11.84)	(5.45)	(41.20)	(268.25)
3	Net Profit for the period before tax (after exceptional items)	8.01	(13.46)	(17.06)	(5.45)	(46.42)	(488.42)
4	Net Profit for the period after tax	8.01	(13.46)	(17.06)	(5.45)	(36.17)	(566.96)
5	Other Comprehensive Income for the period	1.68	(0.01)	0.23	1.67	0.23	0.49
6	Total Comprehensive Income for the period (4 + 5)	9.69	(13.47)	(16.83)	(3.78)	(35.94)	(566.47)
7	Equity Share Capital	40.21	40.21	36.00	40.21	36.00	36.00
8	Other Equity						897.91
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -						
	Basic (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)
	Diluted (Rs.)	2.54	(3.50)	(4.47)	(0.96)	(9.47)	(148.27)

Notes:
1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the NSE Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in).
2. The above consolidated financial results of Solara Active Pharma Sciences Limited ("The Parent" or the Company) and its subsidiaries (together referred to as the "group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 21, 2024. The results for the quarter and six months ended September 30, 2024 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of the review for the quarter and six months ended September 30, 2024.
3. The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 Equity shares of face value of Rs. 10/- each at a price of Rs. 375/- per Equity share (including Share premium of Rs. 365/- per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e. May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act, 2013 and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on 19 June, 2024.
Accordingly, the paid-up equity share capital of the Company has increased from Rs. 36,00,52,670/- divided into 3,60,05,267 fully paid up Equity Shares of face value of Rs. 10 each to Rs.40,20,48,313/- divided into 4,02,04,831 partly paid up Equity Shares of face value of Rs. 10/- each and 1,19,98,755 partly paid up Equity Shares having face value of Rs. 10 each with the Paid up value of Rs. 3,50/- per Share. Pursuant to the Rights issue, earnings per share (EPS) in respect of previous year / periods have been adjusted as per Indian Accounting Standard 33 "Earnings per share", prescribed under Section 133 of the Companies Act, 2013.
For and on behalf of the Board of Directors
Sd/-
Poornav Purohit - MD & CEO
DIN: 10159900

Place : Bengaluru
Date : October 21, 2024

